BerandaHXB • FRA
add
AIM ImmunoTech Inc
Tutup sebelumnya
€6,10
Rentang tahun
€6,10 - €34,40
Kapitalisasi pasar
8,07 jt USD
Rasio P/E
-
Hasil dividen
-
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Mar 2025info | Perubahan Y/Y |
---|---|---|
Pendapatan | 16,00 rb | -60,00% |
Biaya operasional | 3,62 jt | -37,13% |
Laba bersih | -3,70 jt | 36,31% |
Margin laba bersih | -23,16 rb | -59,23% |
Penghasilan per saham | -5,00 | 58,33% |
EBITDA | -3,56 jt | 37,26% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
(USD) | Mar 2025info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 2,25 jt | -79,46% |
Total aset | 6,25 jt | -61,41% |
Total liabilitas | 10,10 jt | -11,07% |
Total ekuitas | -3,86 jt | — |
Saham yang beredar | 764,24 rb | — |
Harga terhadap nilai buku | -1,14 | — |
Tingkat pengembalian aset | -121,80% | — |
Tingkat pengembalian modal | -6.371,48% | — |
Arus Kas
Perubahan kas bersih
(USD) | Mar 2025info | Perubahan Y/Y |
---|---|---|
Laba bersih | -3,70 jt | 36,31% |
Kas dari operasi | -2,36 jt | 50,97% |
Kas dari investasi | 898,00 rb | 668,35% |
Kas dari pembiayaan | 660,00 rb | -76,67% |
Perubahan kas bersih | -803,00 rb | 62,55% |
Arus kas bebas | -1,76 jt | 36,37% |
Tentang
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Didirikan
1966
Kantor pusat
Situs
Karyawan
22